Accuracy of MRI versus CT iMAGing to assess resectability following FOLFIRINOX for locally advancEd pancreatic cancer (IMAGE)

Accuracy of MRI versus CT iMAGing to assess resectability following FOLFIRINOX for locally advancEd pancreatic cancer (IMAGE) - IMAGE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43456

Enrollment

Registered

2016-03-14

Start date

2016-09-29

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer pancreatic carcinoma

Interventions

MRI scan with diffusion weighted imaging (DWI)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with locally advanced pancreatic cancer, without distant metastases, after 2 months of FOLFIRINOX chemotherapy undergoing explorative laparotomy

Exclusion criteria

Exclusion criteria: Contra-indications for MRI

Design outcomes

Primary

Measure	Time frame
Primary outcome measure: correct assessment of tumor resectability according to DWI MRI, compared to standard CT.	—

Secondary

Measure	Time frame
Active tumor size on MRI and CT will be compared, and in patients receiving resection also compared to the active tumor size in the resected pathology specimen.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)